{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    4,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "LY3298176",
        "type": {
          "id": "d16ad6d8-81bd-4fac-bcfe-cfbeac9cf1dc",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "2ee58c4e-809f-4658-9ab1-497a04883f7b",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "A 39-amino acid synthetic peptide with agonist activity at both the GIP and GLP-1 receptors, administered once weekly.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Insulin Glargine",
        "type": {
          "id": "723ec3df-3dac-4de6-a58f-54f3db2b73dc",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "role": {
          "id": "2d69f667-06c2-4387-8c30-7e56d12fa89a",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Basal insulin used as an active comparator, titrated to a fasting blood glucose target of <100 mg/dL.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Metformin",
        "type": {
          "id": "17085d55-94d3-4e00-b044-db632cecca13",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "2f157ac4-6791-4ab8-9ceb-8cfe1b633113",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral antihyperglycemic medication; patients must be on a stable dose for at least 90 days prior to screening.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "SGLT-2 inhibitors",
        "type": {
          "id": "b9720fe8-2682-4abf-a5b4-d8cbf2fb05c1",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "aa42b47c-0c19-404e-84f2-d555ffadcab5",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Sodium-glucose co-transporter-2 inhibitors; oral antihyperglycemic medication.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Sulfonylureas",
        "type": {
          "id": "56c56f69-b2ab-471c-beaa-62edaa864753",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "25ee1b9b-5091-412d-9ef0-2e8b77217221",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral antihyperglycemic medication."
      },
      {
        "id": "int_6",
        "name": "GLP-1 receptor agonists",
        "type": {
          "id": "048b4101-cf96-49e2-ae59-f8a60dc0e4be",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "bda4bef3-10e8-4d66-aeaa-1dfcd00d099d",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited medication during the study."
      },
      {
        "id": "int_7",
        "name": "Amylin analogs",
        "type": {
          "id": "01773769-96cb-426c-81f0-8f9fbf80f113",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "3e3348c2-27a9-4f12-948e-62af8dc4ea32",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited medication during the study."
      },
      {
        "id": "int_8",
        "name": "DPP-4 inhibitors",
        "type": {
          "id": "10bea84a-dfd9-482b-ba9b-f02a6056a7b5",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "db235035-1392-4255-bb37-5210b523dc06",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited medication during the study."
      },
      {
        "id": "int_9",
        "name": "Anti-emetic/Anti-diarrheal medication",
        "type": {
          "id": "30890fd9-6869-436c-8a5e-2b6df189103e",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "96448830-05bc-4000-b002-55d4593ce53d",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted for management of gastrointestinal symptoms."
      },
      {
        "id": "int_10",
        "name": "Paracetamol/acetaminophen",
        "type": {
          "id": "1ea64810-ce00-4d73-8c93-1c5e11f4b807",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "5e767e31-4db3-465f-9def-954384276f29",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted and must be documented in the eCRF."
      },
      {
        "id": "int_11",
        "name": "Aspirin",
        "type": {
          "id": "843a4c87-d0cf-4446-801f-635af6393313",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "8c8050ed-fb50-446c-a9ef-90766fac30b2",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted and must be documented in the eCRF."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "LY3298176 prefilled syringe",
        "administrableDoseForm": {
          "id": "eb3a13db-0f3c-4b8f-814d-35c0c750d753",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "73ceb47c-d8ec-4794-bfd7-d1de1149bcb6",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "abc32868-1db4-4f03-ba4e-9a9b72d8cad9",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "id": "prod_2",
        "name": "Insulin glargine prefilled pen",
        "administrableDoseForm": {
          "id": "5bc8b0e1-3be3-40c8-bc4f-dcccdaf607fc",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "749aba50-dfe0-453b-8753-e832d54b99f3",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "55923f81-bc0b-4a45-819f-5aca8affb621",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "100 units/mL (implied by standard marketed product)",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Eli Lilly and Company (Basaglar)"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "LY3298176 5 mg regimen",
        "instanceType": "Administration",
        "dose": "2.5 mg (Weeks 0-3), then 5 mg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "52 to 104 weeks"
      },
      {
        "id": "admin_2",
        "name": "LY3298176 10 mg regimen",
        "instanceType": "Administration",
        "dose": "2.5 mg (Wks 0-3), 5 mg (Wks 4-7), 7.5 mg (Wks 8-11), 10 mg (Wks 12+)",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "52 to 104 weeks"
      },
      {
        "id": "admin_3",
        "name": "LY3298176 15 mg regimen",
        "instanceType": "Administration",
        "dose": "2.5 mg (Wks 0-3), 5 mg (Wks 4-7), 7.5 mg (Wks 8-11), 10 mg (Wks 12-15), 12.5 mg (Wks 16-19), 15 mg (Wks 20+)",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "52 to 104 weeks"
      },
      {
        "id": "admin_4",
        "name": "Insulin Glargine titration",
        "instanceType": "Administration",
        "dose": "Starting dose 10 IU, titrated based on FBG",
        "doseFrequency": "once daily",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "52 to 104 weeks"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "LY3298176",
        "instanceType": "Substance",
        "description": "GIP and GLP-1 receptor agonist; 39-amino acid synthetic peptide with a C20 fatty di-acid moiety."
      },
      {
        "id": "sub_2",
        "name": "Insulin glargine",
        "instanceType": "Substance",
        "description": "Long-acting basal insulin analogue."
      }
    ],
    "medicalDevices": [
      {
        "id": "dev_1",
        "name": "Investigational prefilled syringe",
        "instanceType": "MedicalDevice",
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "id": "dev_2",
        "name": "Marketed prefilled pen",
        "instanceType": "MedicalDevice",
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "id": "dev_3",
        "name": "Blood glucose meter",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      }
    ],
    "summary": {
      "interventionCount": 11,
      "productCount": 2,
      "deviceCount": 3
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "LY3298176",
        "role": "Investigational Product",
        "description": "A 39-amino acid synthetic peptide with agonist activity at both the GIP and GLP-1 receptors, administered once weekly."
      },
      {
        "name": "Insulin Glargine",
        "role": "Comparator",
        "description": "Basal insulin used as an active comparator, titrated to a fasting blood glucose target of <100 mg/dL."
      },
      {
        "name": "Metformin",
        "role": "Background Therapy",
        "description": "Oral antihyperglycemic medication; patients must be on a stable dose for at least 90 days prior to screening."
      },
      {
        "name": "SGLT-2 inhibitors",
        "role": "Background Therapy",
        "description": "Sodium-glucose co-transporter-2 inhibitors; oral antihyperglycemic medication."
      },
      {
        "name": "Sulfonylureas",
        "role": "Background Therapy",
        "description": "Oral antihyperglycemic medication."
      },
      {
        "name": "GLP-1 receptor agonists",
        "role": "Concomitant Medication",
        "description": "Prohibited medication during the study."
      },
      {
        "name": "Amylin analogs",
        "role": "Concomitant Medication",
        "description": "Prohibited medication during the study."
      },
      {
        "name": "DPP-4 inhibitors",
        "role": "Concomitant Medication",
        "description": "Prohibited medication during the study."
      },
      {
        "name": "Anti-emetic/Anti-diarrheal medication",
        "role": "Concomitant Medication",
        "description": "Permitted for management of gastrointestinal symptoms."
      },
      {
        "name": "Paracetamol/acetaminophen",
        "role": "Concomitant Medication",
        "description": "Permitted and must be documented in the eCRF."
      },
      {
        "name": "Aspirin",
        "role": "Concomitant Medication",
        "description": "Permitted and must be documented in the eCRF."
      }
    ],
    "products": [
      {
        "name": "LY3298176 prefilled syringe",
        "doseForm": "Injection",
        "strength": "2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg",
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "name": "Insulin glargine prefilled pen",
        "doseForm": "Injection",
        "strength": "100 units/mL (implied by standard marketed product)",
        "manufacturer": "Eli Lilly and Company (Basaglar)"
      }
    ],
    "substances": [
      {
        "name": "LY3298176",
        "description": "GIP and GLP-1 receptor agonist; 39-amino acid synthetic peptide with a C20 fatty di-acid moiety."
      },
      {
        "name": "Insulin glargine",
        "description": "Long-acting basal insulin analogue."
      }
    ],
    "administrations": [
      {
        "name": "LY3298176 5 mg regimen",
        "dose": "2.5 mg (Weeks 0-3), then 5 mg",
        "frequency": "once weekly",
        "route": "Subcutaneous",
        "duration": "52 to 104 weeks"
      },
      {
        "name": "LY3298176 10 mg regimen",
        "dose": "2.5 mg (Wks 0-3), 5 mg (Wks 4-7), 7.5 mg (Wks 8-11), 10 mg (Wks 12+)",
        "frequency": "once weekly",
        "route": "Subcutaneous",
        "duration": "52 to 104 weeks"
      },
      {
        "name": "LY3298176 15 mg regimen",
        "dose": "2.5 mg (Wks 0-3), 5 mg (Wks 4-7), 7.5 mg (Wks 8-11), 10 mg (Wks 12-15), 12.5 mg (Wks 16-19), 15 mg (Wks 20+)",
        "frequency": "once weekly",
        "route": "Subcutaneous",
        "duration": "52 to 104 weeks"
      },
      {
        "name": "Insulin Glargine titration",
        "dose": "Starting dose 10 IU, titrated based on FBG",
        "frequency": "once daily",
        "route": "Subcutaneous",
        "duration": "52 to 104 weeks"
      }
    ],
    "devices": [
      {
        "name": "Investigational prefilled syringe",
        "manufacturer": "Eli Lilly and Company",
        "purpose": "Administration of LY3298176"
      },
      {
        "name": "Marketed prefilled pen",
        "manufacturer": "Eli Lilly and Company",
        "purpose": "Administration of insulin glargine"
      },
      {
        "name": "Blood glucose meter",
        "manufacturer": "Not specified",
        "purpose": "Self-monitoring of blood glucose (SMBG)"
      }
    ]
  }
}